Cargando…
Patent and Marketing Exclusivities 101 for Drug Developers
Despite an ever-increasing need for newer, safer, more effective, and more affordable therapies to treat a multitude of diseases and conditions, drug development takes too long, costs too much, and is too uncertain to be undertaken without the conferment of exclusionary rights or entry barriers to m...
Autores principales: | Oronsky, Bryan, Caroen, Scott, Brinkhaus, Franck, Reid, Tony, Stirn, Meaghan, Kumar, Raj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242760/ https://www.ncbi.nlm.nih.gov/pubmed/36635930 http://dx.doi.org/10.2174/1872208317666230111105223 |
Ejemplares similares
-
Data Management 101 for drug developers: A peek behind the curtain
por: Oronsky, Bryan, et al.
Publicado: (2023) -
Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient
por: Kesari, Santosh, et al.
Publicado: (2023) -
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance
por: Oronsky, Bryan, et al.
Publicado: (2015) -
What Exactly Is Inflammation (and What Is It Not?) †
por: Oronsky, Bryan, et al.
Publicado: (2022) -
Going viral: a review of replication-selective oncolytic adenoviruses
por: Larson, Christopher, et al.
Publicado: (2015)